KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Cash (2016 - 2025)

Historic Change in Cash for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $41.0 million.

  • Ionis Pharmaceuticals' Change in Cash rose 104.65% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 12140.36%. This contributed to the annual value of -$157.2 million for FY2024, which is 22801.03% down from last year.
  • Ionis Pharmaceuticals' Change in Cash amounted to $41.0 million in Q3 2025, which was up 104.65% from $33.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Change in Cash's 5-year high stood at $236.2 million during Q4 2021, with a 5-year trough of -$326.7 million in Q1 2022.
  • In the last 5 years, Ionis Pharmaceuticals' Change in Cash had a median value of $22.1 million in 2025 and averaged -$3.1 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Change in Cash tumbled by 208094.72% in 2022 and then skyrocketed by 66204.6% in 2023.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Change in Cash stood at $236.2 million in 2021, then plummeted by 116.31% to -$38.5 million in 2022, then skyrocketed by 222.55% to $47.2 million in 2023, then tumbled by 296.01% to -$92.5 million in 2024, then skyrocketed by 144.35% to $41.0 million in 2025.
  • Its last three reported values are $41.0 million in Q3 2025, $33.1 million for Q2 2025, and $22.1 million during Q1 2025.